Cost-effectiveness of statins for primary and secondary prevention: A continuum of risk model linking WOSCOPs and care

被引：0
|
作者：
Caro, JJ [1 ]
Klittich, W [1 ]
McGuire, A [1 ]
L'Italien, G [1 ]
O'Brien, J [1 ]
Huttin, C [1 ]
Ehreth, J [1 ]
机构：
[1] Univ Paris, F-75252 Paris, France
来源：
ATHEROSCLEROSIS | 1999年 / 144卷
关键词：
D O I：
10.1016/S0021-9150(99)80091-4
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：25 / 25
页数：1
相关论文
共 50 条
  • [1] Establishing the cost-effectiveness of statins in the primary prevention of CHD using a quasi Markov model
    Dewilde, S
    Davies, A
    Hutton, J
    [J]. VALUE IN HEALTH, 2003, 6 (06) : 664 - 665
  • [2] Cost-effectiveness of primary and secondary prevention in cardiovascular diseases
    Troche, CJ
    Tacke, J
    Hinzpeter, B
    Danner, M
    Lauterbach, KW
    [J]. EUROPEAN HEART JOURNAL, 1998, 19 : C59 - C65
  • [3] Cost-Effectiveness of Statins for Primary Cardiovascular Prevention in Chronic Kidney Disease
    Erickson, Kevin F.
    Japa, Sohan
    Owens, Douglas K.
    Chertow, Glenn M.
    Garber, Alan M.
    Goldhaber-Fiebert, Jeremy D.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (12) : 1250 - 1258
  • [4] Cost-effectiveness of primary prevention of myocardial infarction using statins in Germany
    Lauterbach, KW
    Danner, M
    [J]. ATHEROSCLEROSIS XI, 1998, 1155 : 933 - 939
  • [5] Cost-effectiveness of statins for primary prevention of coronary heart disease in Japan
    Ikeda, Shunya
    Kobayashi, Makoto
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 : S225 - S226
  • [6] Beyond 10-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease
    Kohli-Lynch, Ciaran N.
    Lewsey, James
    Boyd, Kathleen A.
    French, Dustin D.
    Jordan, Neil
    Moran, Andrew E.
    Sattar, Naveed
    Preiss, David
    Briggs, Andrew H.
    [J]. CIRCULATION, 2022, 145 (17) : 1312 - 1323
  • [7] Commentary: Beyond 10-year risk: A cost-effectiveness analysis of statins for the primary prevention of cardiovascular disease
    Shah, Aditya
    Sharma, Kamal
    Rawal, Shalin
    Sisodia, Rhea
    Bhatt, Parjanya
    Christian, Cleris
    Konat, Ashwati
    [J]. FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [8] Cost-effectiveness of icosapent ethyl for primary and secondary cardiovascular prevention in the UK
    Michaeli, D. T.
    Michaeli, J. C.
    Boch, T.
    Michaeli, T.
    [J]. EUROPEAN HEART JOURNAL, 2022, 43 : 2845 - 2845
  • [9] Cost-effectiveness of a primary care model for anxiety disorders
    Koenig, Hans-Helmut
    Born, Anja
    Heider, Dirk
    Matschinger, Herbert
    Heinrich, Sven
    Riedel-Heller, Steffi G.
    Surall, Daniel
    Angermeyer, Matthias C.
    Roick, Christiane
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 2009, 195 (04) : 308 - 317
  • [10] COST-EFFECTIVENESS OF STATINS, EZETIMIBE AND PCSK9 INHIBITOR FOR SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE
    Xiang, Y.
    Du, H.
    Gan, L.
    Li, S.
    Hu, M.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S408 - S408
12345